# Clinical Trials Data ALK - Document 10

# Study Phase III Comparison of Superiority, Open With Blind Appraiser, to Evaluate the Efficacy and Safety of Barium Sulphate 66.7% With V (OPTI-BAR) Compared to Proceedings in Inert Radiological Examinations for the Diagnosis of Diseases for Image the Tratogastrointstinal

## Clinical Trial: https://clinicaltrials.gov/study/NCT01629719

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Men and women over 18 who need x-rays gastrointestinal tract with contrast;\n\* Healthy patient, ambulatory;\n\* Willingness to comply with the requirements of the study after signing an informed consent and (hit).\n\nExclusion Criteria:\n\n\* Pregnant or lactating women;\n\* Patients allergic to barium sulfate, latex rubber or simethicone;\n\* Patients who have asthma, eczema, cystic fibrosis, heart disease, high blood pressure, rectal cancer, colostomy, obstruction in the stomach or intestines, pseudotumor cerebri, blocking stomach or intestinal disease, Hirsch or pseudotumor cerebri;\n\* Patients who have recently undergone a rectal biopsy or surgery or a recent history of drilling into your esophagus, stomach or intestines; Patients who have already participated in another clinical protocol in the last six months;\n\* Other clinical criteria that in the opinion of the study investigator could compromise the welfare of the patient or interfere with the results expected from the study.",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Men and women over 18 years.",

Question:  
Based on the following clinical trial information, would a patient with a ALK gene mutation be eligible for the clinical trial?

Answer:  
This trial is about testing x-ray contrast agents in the gastrointestinal tract. The inclusion/exclusion criteria focus on conditions that would make a gastrointestinal x-ray risky or difficult to interpret, or conditions that might otherwise interfere with the study results. An ALK gene mutation is not mentioned.  
  
\*\*A patient with \*only\* an ALK gene mutation would \*likely\* be eligible\*\*, assuming they didn't also have any of the exclusion criteria (pregnancy, allergies, specific GI issues, etc.). However, it's important to note:  
  
\* \*\*ALK mutations are often associated with cancer (especially lung cancer).\*\* Cancer treatment (like chemotherapy) could impact a patient's overall health and potentially exclude them from this trial, even if the ALK mutation itself is not directly disqualifying.   
\* \*\*This trial is specifically for \*healthy\* ambulatory patients.\*\* A patient with cancer, even if being treated for it, might not be considered "healthy" in the context of this trial.  
  
\*\*Ultimately, only the study investigator can determine eligibility.\*\* The patient (or their oncologist) should discuss the ALK mutation and any related health conditions with the trial investigator to confirm eligibility.